By doing this study, we hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to persons with multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy.

Have you been diagnosed with metastatic non-small cell lung cancer? If so, you may be able to take part in a research study looking to compare the safety and effectiveness of pembrolizumab to the investigational drug, ivonescimab in treating this condition.

Have you been diagnosed with metastatic cutaneous melanoma? Have you previously been treated for your melanoma, or maybe it can't be removed? If so, you might be eligible to take part in a study to compare how well a new drug, IMA203, can treat your cancer compared to your physician's choice of treatment.

Do you have Relapsed and Refractory CLL, SLL, or Select Low-grade Lymphomas? Have you received at least 2 or more therapies that have included BTKi and venetoclax? If so, you may be able to take part in a study on a drug called ZE50-0134 to treat patients with these conditions. We will also check if various doses of this medicine are safe for treatment.

In this study, we are looking at a new ultrasound method called contrast-enhanced super-resolution (CESR) imaging. We want to help doctors better understand a patient's risk of cancer.

Have you been diagnosed with CLL or other forms of indolent lymphoma? If so this could be a good study for you to paticipate in. One of the primary goals of this study is To investigate the feasibility of the referral and engagement process in fatigue mitigation intervention for cancer-related fatigue among adults with CLL or other forms of indolent lymphoma.

We want to learn how couples dealing with prostate cancer handle food preparation and eating together.

The purpose of this study is to find out if an investigational treatment called P-BCMA-ALLO1 is safe and will help treat people with Multiple Myeloma. The study is also being done to determine what dose is safe and effective to treat Multiple Myeloma.

The purpose of this study is to determine the recommended ABBV-400 dose when ABBV-400 is given alone (monotherapy) in Stage 1, and to assess if ABBV-400 monotherapy is a safe and effective treatment compared to the standard of care (SOC) LONSURF [Trifluridine and Tipiracil] plus Bevacizumab in subjects with c-Met overexpressed (level of c-Met protein in your tumor cells is increased) uncontrolled metastatic colorectal cancer in Stage 2 of the study plan.

Do you have metastatic colorectal cancer? Does your cancer lack certain mutations? If so, you might be eligible to take part in a trial to look at the effects of an investigational anticancer drug given with normal therapy.